Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
暂无分享，去创建一个
S. Lantuejoul | D. Planchard | O. Molinier | J. Mazières | G. Zalcman | F. Guisier | A. Scherpereel | C. Audigier-Valette | P. Dô | R. Corre | S. Brosseau | F. Morin | I. Monnet | L. Greillier | T. Urban | C. Ligeza-poisson | O. Bylicki | M. Locatelli-Sanchez | E. Amour | D. Moro-Sibilot